Latest Conference Coverage


Aimee W. Smith, PhD: Improving Adherence In Epilepsy

Aimee W. Smith, PhD: Improving Adherence In Epilepsy

December 13th 2019

The assistant professor of psychology at East Carolina University spoke to the challenges of overcoming adherence issues in patients with epilepsy, for whom it is so vital.


Joseph Sullivan, MD: The Benefits of Fenfluramine Treatment in Dravet Syndrome

Joseph Sullivan, MD: The Benefits of Fenfluramine Treatment in Dravet Syndrome

December 12th 2019

The professor of neurology and pediatrics and director of the Pediatric Epilepsy Center at the University of California, San Francisco, discussed his personal experience with fenfluramine and the advantages that the drug may present when treating patients with Dravet syndrome.


Diazepam Buccal Film Comparable to Rectal Gel With Good Safety, Tolerability Profile

Diazepam Buccal Film Comparable to Rectal Gel With Good Safety, Tolerability Profile

December 11th 2019

Full results from the single-dose crossover study requested by the FDA were reported at AES 2019, along with multi-dose safety and efficacy data.


Post-Dose Somnolence With Intranasal Midazolam Not Common, Study Finds

Post-Dose Somnolence With Intranasal Midazolam Not Common, Study Finds

December 11th 2019

Patients were more affected by seizure cluster control and need for additional midazolam dosing than post-dose somnolence.


Early Treatment With Responsive Neurostimulation Linked to Improved Quality of Life and Mood

Early Treatment With Responsive Neurostimulation Linked to Improved Quality of Life and Mood

December 10th 2019

Patients treated with NeuroPace’s Responsive Neurostimulation system within 20 years of epilepsy onset were observed to have significantly better outcomes related to several aspects of quality of life and mood compared to those treated later.


Elizabeth Thiele, MD, PhD: CBD Shows Low-Dose Efficacy and Safety in TSC

Elizabeth Thiele, MD, PhD: CBD Shows Low-Dose Efficacy and Safety in TSC

December 10th 2019

The director of pediatric epilepsy and the Herscot Center for Tuberous Sclerosis Complex at Massachusetts General Hospital, and professor of neurology at Harvard Medical School spoke to the safety outcomes from GWPCARE6 and CBD’s low-dose efficacy.


Infantile Spasm-Associated Hypsarrhythmia May Play Role in Autism Risk

Infantile Spasm-Associated Hypsarrhythmia May Play Role in Autism Risk

December 10th 2019

Study findings suggest that the presence of hypsarrhythmia—abnormal, chaotic brainwave patterns—may play a role in the risk of autism spectrum disorder in patients with a history of infantile spasms.


Ian Miller, MD: Exploring the Advantages of Intranasal Diazepam

Ian Miller, MD: Exploring the Advantages of Intranasal Diazepam

December 10th 2019

The medical director of the Comprehensive Epilepsy Clinic at Nicklaus Children’s Hospital discussed the advantages of intranasal diazepam over traditional midazolam and rectal diazepam.


CBD Improves Non-Seizure Outcomes in Dravet and Lennox-Gastaut Syndromes

CBD Improves Non-Seizure Outcomes in Dravet and Lennox-Gastaut Syndromes

December 10th 2019

Data suggests that treatment with cannabidiol is associated with other benefits besides a decrease in seizure frequency.


Aimee W. Smith, PhD: Addressing Quality of Life In Epilepsy

Aimee W. Smith, PhD: Addressing Quality of Life In Epilepsy

December 9th 2019

The assistant professor of psychology at East Carolina University offered insight about the resources are available to physicians and providers and what techniques can be useful to help patients have a better quality of life in light of refractory and uncontrolled seizures.


Cenobamate Safe, Effective Over Long-Term Treatment

Cenobamate Safe, Effective Over Long-Term Treatment

December 9th 2019

Adjunctive cenobamate demonstrated a good tolerability and safety profile, as well as sustained efficacy, in patients with uncontrolled focal seizures.


Perampanel Proves Positive in Real-World Use in Adolescents With Epilepsy

Perampanel Proves Positive in Real-World Use in Adolescents With Epilepsy

December 9th 2019

In a PROVE study subgroup of adolescent patients exposed to perampanel over a 2-year period, the Eisai product proved to be well-tolerated and efficacious, with good retention rates.


Sumeet Vadera, MD: The Consequences of Forgoing Epilepsy Surgery

Sumeet Vadera, MD: The Consequences of Forgoing Epilepsy Surgery

December 9th 2019

The director of epilepsy surgery and associate professor of neurosurgery at UC Irvine spoke about the consequences of patients choosing to forgo beneficial surgery and the importance of communication between surgeon and epileptologist.


NeuroPace RNS System Shows Continued Success in Interim Post-Approval Results

NeuroPace RNS System Shows Continued Success in Interim Post-Approval Results

December 9th 2019

Interim analysis of a 5-year, post-approval study of the NeuroPace Responsive Neurostimulation system support prior findings that the device is safe and effective in reducing medically intractable focal seizures in adults.


Treatment With Fenfluramine Linked to Improved Executive Function in Dravet Syndrome

Treatment With Fenfluramine Linked to Improved Executive Function in Dravet Syndrome

December 9th 2019

Fenfluramine oral solution is currently being evaluated by the FDA for the treatment of seizures associated with Dravet syndrome.


Telemedicine Feasible For Large-Scale Use in Epilepsy

Telemedicine Feasible For Large-Scale Use in Epilepsy

December 8th 2019

A single-center study of more than 3600 virtual visits displayed a high level of satisfaction from patients regarding their experience with telemedicine and their providers, suggesting the practice may be ready for large-scale use.


Seizure Freedom Persists With Intranasal Midazolam Regardless of Concomitant AEDs

Seizure Freedom Persists With Intranasal Midazolam Regardless of Concomitant AEDs

December 8th 2019

Patients treated with intranasal midazolam who were on enzyme-inducing AEDs experienced numerically lower treatment-emergent adverse events.


Sumeet Vadera, MD: Barriers to Getting Patients to Epilepsy Surgery

Sumeet Vadera, MD: Barriers to Getting Patients to Epilepsy Surgery

December 8th 2019

The director of epilepsy surgery and associate professor of neurosurgery at UC Irvine discussed the challenges he has encountered in getting patients with epilepsy to undergo beneficial procedures, often due to misinformation.


Elizabeth Thiele, MD, PhD: GWPCARE6 Trial of CBD in Tuberous Sclerosis Complex

Elizabeth Thiele, MD, PhD: GWPCARE6 Trial of CBD in Tuberous Sclerosis Complex

December 8th 2019

The director of pediatric epilepsy and the Herscot Center for Tuberous Sclerosis Complex at Massachusetts General Hospital, and professor of neurology at Harvard Medical School discussed the findings of the GWPCARE6 trial of cannabidiol.


American Epilepsy Society Honors Members for Outstanding Contributions

American Epilepsy Society Honors Members for Outstanding Contributions

December 8th 2019

The American Epilepsy Society recognized several members from its clinical and research communities for their outstanding contributions to the field of epilepsy.


Breastfeeding Rates Are Lower Among Women With Epilepsy

Breastfeeding Rates Are Lower Among Women With Epilepsy

December 8th 2019

Despite evidence of the benefits and safety of breastfeeding in women with epilepsy, 2 studies suggest this population breastfeeds significantly less often than women without epilepsy, due to fears of drug exposure or recommendations against the practice.


Diazepam Nasal Spray Demonstrates Good Safety, Tolerability Independent of Usage Frequency

Diazepam Nasal Spray Demonstrates Good Safety, Tolerability Independent of Usage Frequency

December 8th 2019

An analysis of 2 different doses of intranasal diazepam showed consistent safety and tolerability results for repeat dosing


James Wheless, MD: Treating Seizure Clusters With Midazolam

James Wheless, MD: Treating Seizure Clusters With Midazolam

December 8th 2019

The professor and chief of pediatric neurology, and director of the comprehensive epilepsy program and neuroscience institute at Le Bonheur Children’s Hospital offered insight into his experience with midazolam and its potential to play a vital role in treating seizure clusters.


CBD Significantly Reduces Seizures in Tuberous Sclerosis Complex

CBD Significantly Reduces Seizures in Tuberous Sclerosis Complex

December 7th 2019

Patients who were treated with cannabidiol 25 mg or 50 mg experienced seizure reductions of 49% and 48%, respectively, nearly double that of the placebo group, which experienced reductions of 27%.


What to Expect at the 2019 American Epilepsy Society Annual Meeting

What to Expect at the 2019 American Epilepsy Society Annual Meeting

December 3rd 2019

NeurologyLive will be providing live coverage of AES 2019 from Baltimore beginning Saturday, December 7.


Intranasal Diazepam Safe, Tolerable in Pediatric Epilepsy

Intranasal Diazepam Safe, Tolerable in Pediatric Epilepsy

October 29th 2019

Analysis of long-term safety of intranasal diazepam shows favorable results in children and adolescents with cluster or acute, repetitive seizures.


Deflazacort Superior to Prednisone for Treatment of Duchenne Muscular Dystrophy

Deflazacort Superior to Prednisone for Treatment of Duchenne Muscular Dystrophy

October 28th 2019

Study results show that deflazacort tops prednisone across multiple checkpoints in patients with Duchenne muscular dystrophy.


New Assessment May Better Screen Adolescents With Epilepsy for Adult Transition

New Assessment May Better Screen Adolescents With Epilepsy for Adult Transition

October 25th 2019

Epilepsy-specific TRAQ questionnaire shows high validity in pediatric epilepsy patients transitioning to adult epilepsy care.


CBD Shows Long-Term Safety as Add-On Therapy in Lennox-Gastaut Syndrome

CBD Shows Long-Term Safety as Add-On Therapy in Lennox-Gastaut Syndrome

October 25th 2019

Data presented at the Child Neurology Society Annual Meeting suggest that the safety and efficacy of cannabidiol (Epidiolex; GW Pharmaceuticals) is maintained through 72 weeks of treatment for patients with LGS.


Botox Improves Gait, Pain in Pediatric Patients With Lower Limb Spasticity

Botox Improves Gait, Pain in Pediatric Patients With Lower Limb Spasticity

October 24th 2019

The drug recently gained FDA approval for treatment of lower limb spasticity in pediatric patients without cerebral palsy, in which it is associated with improved functional outcomes.

© 2025 MJH Life Sciences

All rights reserved.